Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women.

Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E, Persson IR.

J Natl Cancer Inst. 2002 Apr 3;94(7):497-504.

PMID:
11929950
3.

Hormone replacement therapy and cancer.

[No authors listed]

Gynecol Endocrinol. 2001 Dec;15(6):453-65. Review.

PMID:
11826770
4.

Hormone replacement therapy and epithelial ovarian cancer: is there and association?

Riman T.

J Br Menopause Soc. 2003 Jun;9(2):61-8. Review.

PMID:
12844427
5.

Does smoking increase risk of ovarian cancer? A systematic review.

Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM.

Gynecol Oncol. 2006 Dec;103(3):1122-9. Epub 2006 Sep 26. Review.

PMID:
17005245
6.

Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence.

Riman T, Persson I, Nilsson S.

Clin Endocrinol (Oxf). 1998 Dec;49(6):695-707. Review.

PMID:
10209555
7.

Breast cancer risk with postmenopausal hormonal treatment.

Collins JA, Blake JM, Crosignani PG.

Hum Reprod Update. 2005 Nov-Dec;11(6):545-60. Epub 2005 Sep 8. Review. Erratum in: Hum Reprod Update. 2006 May-Jun;12(3):331.

PMID:
16150813
8.

The role of exogenous hormones in the epidemiology of breast, ovarian and endometrial cancer.

van Leeuwen FE, Rookus MA.

Eur J Cancer Clin Oncol. 1989 Dec;25(12):1961-72. Review.

PMID:
2698811
9.
10.

[Hormone replacement therapy and cancer].

Bjørge T, Tropé C.

Tidsskr Nor Laegeforen. 1997 Jun 10;117(15):2201-7. Review. Norwegian.

PMID:
9235712
11.

Hormone replacement therapy and cancer risk.

Mahavni V, Sood AK.

Curr Opin Oncol. 2001 Sep;13(5):384-9. Review.

PMID:
11555717
12.

[Endometriosis as a risk factor for ovarian cancer].

Vargas-Hernández VM.

Cir Cir. 2013 Mar-Apr;81(2):163-8. Review. Spanish.

PMID:
23522320
13.

Perineal exposure to talc and ovarian cancer risk.

Harlow BL, Cramer DW, Bell DA, Welch WR.

Obstet Gynecol. 1992 Jul;80(1):19-26. Review.

PMID:
1603491
14.

The risks of oral contraceptives and estrogen replacement therapy.

Coe FL, Parks JH.

Perspect Biol Med. 1989 Autumn;33(1):86-106. Review.

PMID:
2689999
15.

Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer.

Weiss NS, Hill DA.

Maturitas. 1996 Mar;23(2):235-9. Review.

PMID:
8735361
16.

Hormone replacement therapy and breast cancer: a qualitative review.

Bush TL, Whiteman M, Flaws JA.

Obstet Gynecol. 2001 Sep;98(3):498-508. Review.

PMID:
11530137
17.

Hormone replacement therapy and gynecological cancer.

Gadducci A, Fanucchi A, Cosio S, Genazzani AR.

Anticancer Res. 1997 Sep-Oct;17(5B):3793-8. Review.

PMID:
9427782
18.

Menopausal hormone therapy and risk of lung cancer-Systematic review and meta-analysis.

Greiser CM, Greiser EM, Dören M.

Maturitas. 2010 Mar;65(3):198-204. doi: 10.1016/j.maturitas.2009.11.027. Epub 2009 Dec 23. Review.

PMID:
20031346
19.

Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis.

Li D, Ding CY, Qiu LH.

Gynecol Oncol. 2015 Nov;139(2):355-62. doi: 10.1016/j.ygyno.2015.07.109. Epub 2015 Jul 29. Review.

PMID:
26232517
20.

[Prevalence of endometriosis in ovarian cancer].

Iwase H, Yoshikawa H.

Nihon Rinsho. 2001 Jan;59 Suppl 1:208-12. Review. Japanese. No abstract available.

PMID:
11235167

Supplemental Content

Support Center